Gilead pipeline：Press Releases
Press Releases
2023年5月9日—GileadStrengthensEarlyPipelineinOncologyandInflammationThroughtheAcquisitionofXinThera.–AcquisitionofXinTheraProvides ...。其他文章還包含有：「GileadSciences」、「GileadShowcasesLatestHIVPipelineProgressandthe...」、「GrowthinOncologyPrograms」、「Oncology」、「OurScience」、「OurTherapeuticAreas」、「Research」、「Virology」
查看更多 離開網站
Gilead Sciences
https://www.gilead.com
Gilead Sciences, Inc. is a research-based biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines.
Gilead Showcases Latest HIV Pipeline Progress and the ...
https://www.gilead.com
Gilead Showcases Latest HIV Pipeline Progress and the Impact of Global Collaboration on Health Equity Efforts at IAS 2023.
Growth in Oncology Programs
https://www.gilead.com
The result: we have increased our pipeline by 50% overall, as measured by asset-indication projects, with direct ownership of 12 new molecules and the right to ...
Oncology
https://www.gilead.com
Our pipeline includes many promising targets and approaches in oncology today, from antibody-drug conjugates and small molecules to cell therapy-based ...
Our Science
https://www.gilead.com
Gilead and Kite Oncology's portfolio includes four approved medicines including Trodelvy® (sacituzumab govitecan-hziy) and Zydelig® (idelalisib) as well as CAR ...
Our Therapeutic Areas
https://www.gilead.com
Today, we have a robust portfolio and pipeline spanning virology, oncology and inflammation. We will continue relentlessly innovating in these therapeutic ...
Research
https://www.gilead.com
Learn More About Our Research Pipeline Our research and development programs currently focus on potential treatments in HIV, viral hepatitis, ...
Virology
https://www.gilead.com
Meta Description Learn about the investigational medicines in Gilead's pipeline with the potential to help advance care in HIV, cancer, ...